1. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 2004;116:281297.
2. Võsa U, Vooder T, Kolde R, et al. Meta-analysis of microRNA expression in lung cancer. Int J
Cancer 2013;132:2884-2893.
3. Markou A, Sourvinou I, Vorkas PA, et al. Clinical evaluation of microRNA expression profiling
in non small cell lung cancer. Lung Cancer 2013;81:388-396. Available at:
http://dx.doi.org/10.1016/j.lungcan.2013.05.007.
4. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers
for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006. Available at:
http://www.nature.com/articles/cr2008282.
5. Jin X, Chen Y, Chen H, et al. Evaluation of Tumor-Derived Exosomal miRNA as Potential
Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation
Sequencing. Clin Cancer Res 2017;23:5311-5319. Available at:
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-0577.
6. Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small
cell lung cancer. Lung Cancer 2010;67:170-176. Available at:
http://linkinghub.elsevier.com/retrieve/pii/S0169500209002153.
7. Huang W, Hu J, Yang DW, et al. Two microRNA panels to discriminate three subtypes of lung
carcinoma in bronchial brushing specimens. Am J Respir Crit Care Med 2012;186:1160-1167.
8. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007;26:2799-2803.
9. Chan S-H, Wu C-W, Li AFY, et al. miR-21 microRNA expression in human gastric carcinomas
and its clinical association. Anticancer Res 2008;28:907-11. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/18507035.
10. Wang LJ, He CC, Sui X, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation
and growth in vitro and in vivo by targeting PTPN14 and PTEN¥r. Oncotarget¥r 2015;6:546-5932.
11. Li L, Wang X, Li W, et al. miR-21 modulates prostaglandin signaling and promotes gastric
tumorigenesis by targeting 15-PGDH. Biochem Biophys Res Commun 2018;495:928-934. Available
at: https://doi.org/10.1016/j.bbrc.2017.09.137.
12. Jiang M, Li X, Quan X, et al. Clinically Correlated MicroRNAs in the Diagnosis of Non-Small
Cell Lung Cancer: A Systematic Review and Meta-Analysis. Biomed Res Int 2018;2018.
13. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis
by MicroRNA-21. Cancer Cell 2010;18:282-293. Available at:
http://dx.doi.org/10.1016/j.ccr.2010.08.013.
14. Zhang J guang, Wang J jun, Zhao F, et al. MicroRNA-21 (miR-21) represses tumor suppressor
PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta
2010;411:846-852. Available at: http://dx.doi.org/10.1016/j.cca.2010.02.074.
15. Xia H, Zhang W, Zhang B, et al. miR-21 modulates the effect of EZH2 on the biological
behavior of human lung cancer stem cells in vitro. Oncotarget 2017;8:85442-85451.
16. Liu XG, Zhu WY, Huang YY, et al. High expression of serum miR-21 and tumor miR-200c
associated with poor prognosis in patients with lung cancer. Med Oncol 2012;29:618-626.
17. Wang ZX, Bian HB, Wang JR, et al. Prognostic significance of serum miRNA-21 expression in
human non-small cell lung cancer. J Surg Oncol 2011;104:847-851.
18. Xu RS, Wu XD, Zhang SQ, et al. The tumor suppressor gene RhoBTB1 is a novel target of miR31 in human colon cancer. Int J Oncol 2013;42:676-682.
19. Zheng W, Liu Z, Zhang W, et al. miR-31 functions as an oncogene in cervical cancer. Arch
Gynecol Obstet 2015;292:1083-1089. Available at: http://dx.doi.org/10.1007/s00404-015-3713-2.
20. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in
mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest
2010;120:1298-1309.
21. Edmonds MD, Boyd KL, Moyo T, et al. MicroRNA-31 initiates lung tumorigenesis and
promotes mutant KRAS-driven lung cancer. J Clin Invest 2016;126:349-364.
22. Ichiyama K, Gonzalez-Martin A, Kim B-S, et al. The MicroRNA-183-96-182 Cluster Promotes
T Helper 17 Cell Pathogenicity by Negatively Regulating Transcription Factor Foxo1 Expression.
Immunity 2016;44:1284-1298. Available at:
https://linkinghub.elsevier.com/retrieve/pii/S1074761316302035.
23. Weeraratne SD, Amani V, Teider N, et al. Pleiotropic effects of miR-183̃96̃182 converge to
regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol
2012;123:539-552.
24. Li P, Sheng C, Huang L, et al. MiR-183/-96/-182 cluster is up-regulated in most breast cancers
and increases cell proliferation and migration. Breast Cancer Res 2014;16:1-17.
25. Zhu WY, Zhou KY, Zha Y, et al. Diagnostic Value of Serum miR-182, miR-183, miR-210, and
miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS One 2016;11:1-16.
26. Zhu W, Liu X, He J, et al. Overexpression of members of the microRNA-183 family is a risk
factor for lung cancer: A case control study. BMC Cancer 2011;11:393. Available at:
http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-393.
27. Li G, Li M, Hu J, et al. The microRNA-182-PDK4 axis regulates lung tumorigenesis by
modulating pyruvate dehydrogenase and lipogenesis. Oncogene 2017;36:989-998.
28. Chang H, Liu YH, Wang LL, et al. Mir-182 promotes cell proliferation by suppressing fbxw7
and fbxw11 in non-small cell lung cancer. Am J Transl Res 2018;10:1131-1142.
29. Sarver AL, Li H, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the
transcription factor EGR1 and promoting tumor cell migration. Cancer Res 2010;70:9570-9580.
30. Kirschner MB, Kao SC, Edelman JJ, et al. Haemolysis during Sample Preparation Alters
microRNA Content of Plasma. PLoS One 2011;6:e24145. Available at:
https://doi.org/10.1371/journal.pone.0024145.
31. Teruel-Montoya R, Kong X, Abraham S, et al. MicroRNA Expression Differences in Human
Hematopoietic Cell Lineages Enable Regulated Transgene Expression. PLoS One 2014;9:e102259.
Available at: https://doi.org/10.1371/journal.pone.0102259.
32. Pavel AB, Campbell JD, Liu G, et al. Alterations in Bronchial Airway miRNA Expression for
Lung Cancer Detection. Cancer Prev Res 2017;10:651-659. Available at:
http://cancerpreventionresearch.aacrjournals.org/lookup/doi/10.1158/1940-6207.CAPR-17-0098.
33. Sun Y, Fang R, Li C, et al. Hsa-mir-182 suppresses lung tumorigenesis through down regulation
of RGS17 expression in vitro. Biochem Biophys Res Commun 2010;396:501-507. Available at:
http://dx.doi.org/10.1016/j.bbrc.2010.04.127.
34. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells.
FEBS Lett 2008;582:3663-3668. Available at: http://dx.doi.org/10.1016/j.febslet.2008.09.051.
35. Fujii T, Asano A, Shimada K, et al. Evaluation of RNA and DNA extraction from liquid-based
cytology specimens. Diagn Cytopathol 2016;44:833-840. Available at:
http://doi.wiley.com/10.1002/dc.23524.
36. Schwarzenbach H, Silva AM da, Calin G, et al. Which is the accurate data normalization strategy
for microRNA quantification? Clin Chem 2015;61:1333-1342.
Table 1. Clinical characteristics of 18 NSCLC patients
Table 2. Clinical characteristics of 125 patients
Table 3. Relationship of case numbers examined by RT-qPCR for 4 miRNAs between histological
diagnosis and cytologic classification
Figure 1. Selection protocol for liquid-based cytological specimens. (Number of cases histologically
diagnosed cancerous (T) or non-cancerous (N))
Figure 2. Relative expression of miR-21(A), miR-31(B), miR-182(C), and miR-183(D) in lung cancer
tissues and adjacent non-cancerous tissues. Four miRNAs were significantly up-regulated in cancer
tissues. T: lung cancer tissues, N: adjacent non-cancerous tissues. *Pʽ0.05 **Pʽ0.01
Figure 3. Relative expression of each miRNA in cytological samples. Four miRNAs were significantly
up-regulated in samples obtained from cases finally diagnosed as cancerous(A-D). T: Cases finally
diagnosed as cancer. N: Cases finally diagnosed as non-cancer. *Pʽ0.05 **Pʽ0.01
Figure 4. Relative expression of each miRNA in cytological samples judged as benign or indeterminate.
Four miRNAs were significantly up-regulated in samples obtained from cases histologically diagnosed
as cancerous in comparison with samples obtained from cases histologically diagnosed as noncancerous(A-D). T: Cases finally diagnosed as cancer. N: Cases finally diagnosed as non-cancer. *p
ʽ0.05 **pʽ0.01
Figure 5. ROC curve analysis of diagnostic value in cytological samples diagnosed as benign.
ROC curve with corresponding the area under the ROC curve for each miRNA expression in LBC
from cancer cases vs. non-cancer cases (A-D). ROC curve with corresponding the area under the ROC
curve for 4 combined miRNA expression in LBC from cancer cases vs. non-cancer cases (E). The
diagnostic value of 4 combined miRNAs was better than each individual miRNA.
Supplemental figure 1. The difference of Ct value between Magcore® and manual isolation kit.
The detected expression levels of miRs extracted by Magcore® were lower than that detected by an
manual isolation kit
Supplemental figure 2. The correlation between each miR and clinical stage. There was no significant
correlation between each miR and clinical stage.
Supplemental figure 3.
The expression of each miR by tumor subtype. There was no significant difference between each tumor
subtype.
N: cases finally diagnosed as non-cancer. Ad: cases diagnosed as adenocarcinoma. Sq: cases diagnosed
squamous cell carcinoma. Small: cases diagnosed as small cell lung cancer. *pʽ0.05, **pʽ0.005.
Table 1. Clinical characteristics of 18 NSCLC patients
Table 2. Clinical characteristics of 125 patients
Table 3. Relationship of case numbers examined by RT-qPCR for 4 miRNAs between histological
diagnosis and cytologic classification
Figure 1. Selection protocol for liquid-based cytological specimens. (Number of cases histologically
diagnosed cancerous (T) or non-cancerous (N))
)LJXUH 5HODWLYH H[SUHVVLRQ RI PL5$ PL5% PL5& DQG PL5' LQ OXQJ FDQFHU
WLVVXHVDQGDGMDFHQWQRQFDQFHURXVWLVVXHV
)RXUPL51$VZHUHVLJQLILFDQWO\XSUHJXODWHGLQFDQFHUWLVVXHV
7 OXQJFDQFHUWLVVXHV1 DGMDFHQWQRQFDQFHURXVWLVVXHV
Sʽ Sʽ
)LJXUH5HODWLYHH[SUHVVLRQRIHDFKPL51$LQF\WRORJLFDOVDPSOHV
)RXU PL51$V ZHUH VLJQLILFDQWO\ XSUHJXODWHG LQ VDPSOHV REWDLQHG IURP FDVHV ILQDOO\ GLDJQRVHG DV
FDQFHURXV$'
7 &DVHVILQDOO\GLDJQRVHGDVFDQFHU1 &DVHVILQDOO\GLDJQRVHGDVQRQFDQFHU
Sʽ Sʽ
)LJXUH5HODWLYHH[SUHVVLRQRIHDFKPL51$LQF\WRORJLFDOVDPSOHVMXGJHGDVEHQLJQRULQGHWHUPLQDWH
)RXUPL51$VZHUHVLJQLILFDQWO\XSUHJXODWHGLQVDPSOHVREWDLQHGIURPFDVHVKLVWRORJLFDOO\GLDJQRVHGDV
FDQFHURXVLQFRPSDULVRQZLWKVDPSOHVREWDLQHGIURPFDVHVKLVWRORJLFDOO\GLDJQRVHGDVQRQFDQFHURXV$
'
7 &DVHVILQDOO\GLDJQRVHGDVFDQFHU1 &DVHVILQDOO\GLDJQRVHGDVQRQFDQFHU
Sʽ Sʽ
)LJXUH52&FXUYHDQDO\VLVRIGLDJQRVWLFYDOXHLQF\WRORJLFDOVDPSOHVGLDJQRVHGDVEHQLJQ
52&FXUYHZLWKFRUUHVSRQGLQJWKHDUHDXQGHUWKH52&FXUYHIRUHDFKPL51$H[SUHVVLRQLQ/%&IURP
FDQFHUFDVHVYVQRQFDQFHUFDVHV$'52&FXUYHZLWKFRUUHVSRQGLQJWKHDUHDXQGHUWKH52&FXUYHIRU
FRPELQHGPL51$H[SUHVVLRQLQ/%&IURPFDQFHUFDVHVYVQRQFDQFHUFDVHV(7KHGLDJQRVWLFYDOXHRI
FRPELQHGPL51$VZDVEHWWHUWKDQHDFKLQGLYLGXDOPL51$
6XSSOHPHQWDOILJXUH7KHGLIIHUHQFHRI&WYDOXHEHWZHHQ0DJFRUHDQGPDQXDOLVRODWLRQNLW
7KHGHWHFWHGH[SUHVVLRQOHYHOVRIPL5VH[WUDFWHGE\0DJFRUHZHUHORZHUWKDQWKDWGHWHFWHGE\DPDQXDO
LVRODWLRQNLW
6XSSOHPHQWDOILJXUH7KHFRUUHODWLRQEHWZHHQHDFKPL5DQGFOLQLFDOVWDJH
7KHUHZDVQRVLJQLILFDQWFRUUHODWLRQEHWZHHQHDFKPL5DQGFOLQLFDOVWDJH
6XSSOHPHQWDOILJXUH7KHH[SUHVVLRQRIHDFKPL5E\WXPRUVXEW\SH
7KHUHZDVQRVLJQLILFDQWGLIIHUHQFHEHWZHHQHDFKWXPRUVXEW\SH
1 FDVHV ILQDOO\ GLDJQRVHG DV QRQFDQFHU $G FDVHV GLDJQRVHG DV DGHQRFDUFLQRPD 6T FDVHV GLDJQRVHG
VTXDPRXVFHOOFDUFLQRPD6PDOO FDVHVGLDJQRVHGDVVPDOOFHOOOXQJFDQFHU
Sʽ
Sʽ
...